(CercleFinance.com) – AstraZeneca reports that a phase III trial of Imfinzi (durvalumab) did not reach statistical significance for the primary endpoint of progression-free survival (PFS) compared to placebo in lung cancer Early-stage non-small cell (NSCLC) (IB-IIIA) after complete tumor resection in patients whose tumors express PD-L1 on 25% or more of the tumor cells.
‘We are disappointed by the results of the trial. Imfinzi has helped change the therapeutic landscape and has achieved several positive results in Phase III trials for patients with earlier-stage lung cancer,’ commented Susan Galbraith, Executive Vice President, Oncology R&D at AstraZeneca .
“We remain committed to addressing unmet needs in lung cancer through our extensive development program,” she added.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
